Target Name: CD1B
NCBI ID: G910
Review Report on CD1B Target / Biomarker Content of Review Report on CD1B Target / Biomarker
CD1B
Other Name(s): CD1b | CD1B_HUMAN | Cortical thymocyte antigen CD1B | MGC125991 | MGC125990 | CD1A | CD1B antigen | CD1b antigen | CD1b molecule | T-cell surface glycoprotein CD1b | T-cell surface glycoprotein CD1b [Precursor] | Differentiation antigen CD1-alpha-3 | CD1 | CD1B antigen, b polypeptide | differentiation antigen CD1-alpha-3 | R1 | cortical thymocyte antigen CD1B

CD1B: A Potential Drug Target and Biomarker for the Treatment of Inflammatory Diseases

Introduction

CD1B (Complement receptor 1B) is a protein that is expressed in various tissues throughout the body, including the immune system, skin, and mucous membranes. It plays a crucial role in the immune response by allowing white blood cells to recognize and bind foreign particles , such as bacteria, viruses, and debris from damaged tissue. CD1B is also involved in inflammation, and its dysfunction has been implicated in a number of inflammatory diseases, including rheumatoid arthritis, chronic obstructive pulmonary disease (COPD), and inflammatory bowel disease ( IBD).

CD1B has also been identified as a potential drug target for the treatment of inflammatory diseases. By targeting the CD1B receptor, drugs can reduce inflammation, improve immune function, and treat a range of inflammatory disorders. In this article, we will explore the biology of CD1B, its potential as a drug target, and the research being conducted to develop treatments for inflammatory diseases.

The Biology of CD1B

CD1B is a transmembrane protein that is composed of an extracellular portion and an intracellular portion. The intracellular portion of CD1B consists of a nucleotide-binding oligomerization domain (NBD), a cytoplasmic domain, and a transmembrane region. The NBD is responsible for the binding of CD1B to its complement protein, while the cytoplasmic domain is involved in the formation of the protein complex with the complement. The transmembrane region is responsible for maintaining the stability of the protein and for its interactions with other molecules.

CD1B is involved in the immune response by allowing white blood cells to recognize and bind to foreign particles. When a pathogen enters the body, CD1B is expressed in the liver and spleen, and it is involved in the recruitment of neutrophils to the site of infection . CD1B is also involved in the phagocytosis of bacteria and other pathogens, and it has been shown to play a role in the regulation of inflammation.

CD1B dysfunction has been implicated in a number of inflammatory diseases, including rheumatoid arthritis, COPD, and IBD. Studies have shown that individuals with rheumatoid arthritis have lower levels of CD1B in their blood than those without the disease, and that CD1B blockade drugs can improve symptoms in these individuals. Similarly, studies have shown that individuals with COPD have lower levels of CD1B in their airways than those without the disease, and that CD1B blockade drugs can improve lung function in these individuals.

Potential Drug Targets

CD1B is a protein that has been identified as a potential drug target for the treatment of inflammatory diseases. By targeting the CD1B receptor, drugs can reduce inflammation, improve immune function, and treat a range of inflammatory disorders. There are several different approaches that can be used to target the CD1B receptor, including:

1. Small molecule inhibitors: These drugs work by binding to the CD1B receptor and inhibiting its function. Small molecule inhibitors have been shown to be effective in animal models of rheumatoid arthritis and COPD.
2. Monoclonal antibodies: These drugs work by binding to a specific protein and blocking its function. Monoclonal antibodies have been shown to be effective in treating a range of inflammatory disorders, including rheumatoid arthritis and COPD.
3. Peptide-conjugated nanoparticles: These drugs work by delivering a payload of a therapeutic agent directly to the CD1B receptor. Peptide-conjugated nanoparticles have been shown to be effective in animal models of rheumatoid arthritis and COPD.

CD1B as a Biomarker

CD1B is also being used as a biomarker for the diagnosis and monitoring of inflammatory diseases. By measuring the level of CD1B in blood or other body tissues, doctors can determine the level of inflammation in the body and monitor the effectiveness of treatments. For example, studies have shown that individuals with rheumatoid arthritis have lower levels of CD1B in their blood than those without the disease, and that CD1B blockade drugs can improve symptoms in these individuals. Similarly, studies have shown that individuals with COPD have lower levels of CD1B in their airways than those without the disease, and that CD1B blockade drugs can improve lung function in these individuals.

Conclusion

CD1B is a protein that is involved in the immune response and is expressed in various tissues throughout the body. Its dysfunction has been implicated in a number of inflammatory diseases, including rheumatoid arthritis, COPD, and I

Protein Name: CD1b Molecule

Functions: Antigen-presenting protein that binds self and non-self lipid and glycolipid antigens and presents them to T-cell receptors on natural killer T-cells

The "CD1B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD1B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C